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Abstract 
Objective: To investigate the effects of single doses of a selective serotonin 
reuptake inhibitor (SSRI) on lower limb voluntary and reflex function in 
individuals with chronic stroke. 
Design: Double-blind, randomized, placebo-controlled crossover trial. 
Setting: Outpatient research setting. 
Participants: Individuals (N=10; 7 men; mean age ± SD, 57±10y) with 
poststroke hemiplegia of >1 year duration who completed all assessments. 
Interventions: Patients were assessed before and 5 hours after single-dose, 
overencapsulated 10-mg doses of escitalopram (SSRI) or placebo, with 1 
week between conditions. 
Main Outcome Measures: Primary assessments included maximal ankle and 
knee isometric strength, and velocity-dependent (30°/s–120°/s) plantarflexor 
stretch reflexes under passive conditions, and separately during and after 3 
superimposed maximal volitional drive to simulate conditions of increased 
serotonin release. Secondary measures included clinical measures of lower 
limb coordination and locomotion. 
Results: SSRI administration significantly increased stretch reflex torques at 
higher stretch velocities (eg, 90°/s; P=.03), with reflexes at lower velocities 
enhanced by superimposed voluntary drive (P=.02). No significant 
improvements were seen in volitional peak torques or in clinical measures of 
lower limb function (lowest P=.10). 
Conclusions: Increases in spasticity but not strength or lower limb function 
were observed with single-dose SSRI administration in individuals with 
chronic stroke. Further studies should evaluate whether repeated dosing of 
SSRIs, or as combined with specific interventions, is required to elicit 
significant benefit of these agents on lower limb function poststroke. 
 
Keywords: Muscle spasticity, Muscle strength, Rehabilitation, Serotonin, 
Stroke 
 
List of abbreviations 
 5-HT, 5-hydroxytryptamine (serotonin);  
 MG, medial gastrocnemius;  
 MVC, maximum volitional contraction;  
 SCI, spinal cord injury;  
 6MWD, 6-minute walking distance;  
 SSRI, selective serotonin reuptake inhibitor;  
 TA, tibialis anterior;  
 UMN, upper motor neuron 
Unilateral stroke produces the characteristic upper motor neuron 
(UMN) syndrome, which includes “positive” signs of spasticity1,2 and 
“negative” signs of hemiparesis3,4 and disrupted coordination.5,6 While 
increased spasticity is considered a major barrier for recovery of 
function,1,7,8,9 evidence suggests that weakness is the primary 
determinant of motor function of both lower and upper extremities.4,10, 
11,12,13 Most strategies to enhance strength poststroke focus on physical 
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training and electrical stimulation paradigms, whereas pharmacologic 
interventions are directed primarily to decrease spasticity14,15,16 rather 
than to increase strength. 
Previous data suggest that selective serotonin reuptake 
inhibitors (SSRIs) may mitigate weakness17 and improve function 
poststroke.18,19,20 In general, SSRIs facilitate 5-hydroxytryptamine 
(serotonin) (5-HT) transmission by decreasing presynaptic 
sequestration in axon terminals originating primarily from brainstem 
(raphe) projections.21 Such pathways are active during wakefulness 
with increased activity during rhythmic, repetitive movements such as 
locomotion.22,23 While the central effects of 5-HT are complex, the net 
result on motor systems is excitatory.24,25 In humans poststroke, most 
studies using SSRIs or other 5-HT reuptake inhibitors (eg, fluoxetine, 
paroxetine, venlafaxine) focus on the upper extremity and indicate 
enhanced cortical excitability and motor performance in subacute and 
chronic stroke (grip strength, rate of finger tap, and 9-hole peg 
test17,20,26). Interestingly, with repeated SSRI administration, data 
from intact individuals demonstrate potential decreased motor cortical 
excitability,27,28 while studies19,29 with patients early poststroke 
undergoing rehabilitation indicate improved motor recovery. Although 
changes in lower extremity function have not been well studied 
poststroke, single-dose SSRI (escitalopram) administration may 
improve leg strength in chronic, incomplete spinal cord injury 
(SCI).30,31 
Despite the focus on increased supraspinal excitability with 
SSRIs, these agents may also increase spinal excitability.32,33 For 
example, longstanding and recent data in human SCI30,31,34 suggest 
increased spastic motor activity after single or repeated doses of 
SSRIs, although similar findings have not been reported in patients 
with stroke. In 1 study,35 greater antagonist muscle activity was 
observed during volitional upper extremity motor tasks after use of an 
SSRI poststroke, with no changes in strength or task performance. 
However, spasticity was not assessed. Whether the findings of 
increased spasticity with SSRIs are selective to patients with SCI or 
attributable to differences in the extremities tested is not clear. 
Increased spasticity with SSRI administration poststroke may be of 
interest to rehabilitation professionals because spastic hypertonia with 
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UMN syndrome is still considered by many to be a major barrier to 
functional recovery.8,9 
The objective of this study was to determine the effects of single 
SSRI doses on lower extremity motor function in patients with chronic 
stroke. Using a double-blind, randomized, placebo-controlled crossover 
design, we hypothesized that SSRIs would increase volitional strength 
in patients with chronic hemiparesis poststroke, consistent with data 
from upper extremity studies and patients with incomplete SCI. We 
focused on the single-dose effects here to minimize potential 
habituation with repeated SSRI use,27,28 and because of the potential 
increase in spasticity that may interfere immediately with lower limb 
function or patient comfort. Considering the potential effects on spinal 
excitability,36,37 we also evaluated the effects of SSRIs on stretch 
reflexes during passive (resting) conditions, and during and after 
rhythmic, repeated volitional tasks designed to simulate conditions of 
increased 5-HT release.22,23 The immediate effects of SSRIs on lower 
limb motor function are of clinical interest given their common use for 
treatment of depressive symptoms in this patient population,38 and the 
potential consequences of altering motor function during functional 
tasks. 
Methods 
Participants 
Individuals with chronic (>1y) hemiparesis after unilateral 
supratentorial stroke, and lower extremity Fugl-Meyer scores <3439 
were recruited. Additional criteria included passive ankle range of 
motion from 0° to 30° plantarflexion, Modified Ashworth Scale score 
≥1 of the paretic plantarflexors,40 and the ability to ambulate without 
physical assistance but with assistive devices and below-knee orthoses 
if necessary. Exclusion criteria included use of oral antispastic 
medications <14 days previously or receiving a botulinum toxin 
injection <6 months ago, the presence of uncontrolled 
cardiorespiratory or metabolic diseases, or having a score <23/30 on 
the Mini-Mental State Examination.41 Written consent was obtained 
from all subjects, with procedures approved by the local ethics 
committee. A sample size of 10 individuals was targeted from previous 
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findings in patients with stroke with fewer subjects (n=4–817 and 20) and 
data of altered volitional strength after single-dose SSRI assessments 
in human SCI.30 Power analyses from the latter data indicate that 10 
subjects would provide 91% power (effect size, 1.34). 
Study protocol 
Subjects were randomly assigned to receive 10mg of 
escitalopram on day 1 and placebo (microcrystalline cellulose) on day 
2, or with the order reversed. The half-life of escitalopram is 27 
hours,42 and 7 days between testing ensured drug elimination before 
reassessment. Agents were overencapsulated and block randomized (4 
subjects per block) by the pharmacist who maintained blinding. 
Subjects were tested before and 4 to 5 hours after drug administration 
(time for peak plasma concentration42). Testing was completed in 1.5 
to 2 hours, and the time of day was similar for all procedures across 
drug conditions (ie, morning for pretesting, afternoon for posttraining). 
The randomization code was broken after all completed analysis. 
Figure 1 provides a schematic of the study design. 
 
Fig 1. Schematic of study protocol and timing of testing. 
Experimental session 
Biomechanical measures of lower extremity strength and 
reflexes, and clinical assessments were performed in the same order 
during each session. Clinical assessments were obtained in the 
beginning of each session and consisted of lower extremity Fugl-Meyer 
scores, 6-minute walking distance (6MWD) at subject's normal 
comfortable speed, and the fastest gait speeds over 10m. 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Archives of Physical Medicine and Rehabilitation, Vol 96, No. 12 (December 2015): pg. 2112-2119. DOI. This article is © 
Elsevier (WB Saunders) and permission has been granted for this version to appear in e-Publications@Marquette. Elsevier 
(WB Saunders) does not grant permission for this article to be further copied/distributed or hosted elsewhere without 
the express permission from Elsevier (WB Saunders). 
6 
 
Biomechanical measures were obtained using an isokinetic 
dynamometer (Biodexa) with an attached 6-degree-of-freedom load 
cell.b For ankle measures, subjects were seated with the foot secured 
in a footplate coupled to the load cell/Biodex, and the ankle and 
Biodex motor axes were aligned,43 with the knee and hip at 0° and 75° 
flexion, respectively. For knee measures, the Biodex and knee axes 
were aligned with the shank secured to an attachment. Position and 
velocity signals were recorded from Biodex transducers. All signals 
were sampled at 1000Hz using data acquisition cards and custom 
software.c Surface electromyographic activity was recorded by active 
electrodesd on the paretic tibialis anterior (TA), medial gastrocnemius 
(MG), and soleus. Signals were amplified (1000×) and filtered (20–
450Hz) before sampling. Torque and electromyographic signals were 
measured during the following tasks: maximal volitional contractions 
(MVCs) of knee flexion/extension and ankle plantarflexion/dorsiflexion; 
passive paretic plantarflexor stretches; and passive and active-assist 
stretch responses. To normalize electromyographic measures, the 
maximum M wave was elicited through 1-millisecond stimuli applied to 
the tibial or peroneal nerve to elicit a maximum response of paretic TA 
and MG recordings. 
Isometric MVC tasks 
Three MVCs, each 3 to 5 seconds in duration, were performed 
with ≥60 seconds of rest between trials. MVCs were tested in neutral 
position (90° angle) for plantarflexion torques and at 30° 
plantarflexion for dorsiflexion MVCs. Knee extension MVCs were 
performed at 90° flexion and knee flexion MVCs at 30° flexion. 
Passive plantarflexor stretch 
Torques and electromyographic activity were measured during 
passive, paretic plantarflexor stretch through controlled velocity 
(ramp) ankle rotations from 30° to 0° at constant speeds (5, 30, 60, 
90, or 120°/s). Each stretch was held for 10 seconds, and 3 stretch 
reflexes were recorded at each speed with ≥60 seconds between trials. 
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Passive and active-assist trials 
Repeated MVCs during controlled ankle movements were 
performed to assess the effects of SSRIs on combined volitional and 
reflex behaviors during tasks that presumably increase brainstem 5-HT 
release.22,23 These effects were assessed during 6 consecutive cycles of 
passive and active-assist trials at 60°/s through the 30° range, with 3 
seconds between rotations. Subjects relaxed during the first cycle 
(passive cycle), followed by 3 repeated, concentric MVCs of paretic 
dorsiflexors and plantarflexors during the second to fourth joint 
rotations (active assist cycles), and then 2 subsequent passive cycles 
(fifth and sixth cycles). Subjects were provided verbal cues to start 
each MVC approximately 1 second before passive movement. 
Data analysis 
Custom MATLABe programs were used to analyze data. Torque 
signals were low-pass filtered at 20Hz (fourth-order Butterworth filter 
applied forward and backward). Torque and angle data during slow 
(5°/s) stretches were fitted with sixth-order polynomials and 
subtracted from faster trials to differentiate gravitational/passive 
torques from reflex response.44 Electromyographic data were band-
stop filtered at 55 to 65Hz. The root mean square electromyographic 
activity was calculated using a 50-point moving window. The 
electromyographic signal was normalized to the M-wave amplitude 
from TA and MG obtained during each session. Recordings from the 
soleus were nondetectable in 5 of 10 subjects, and only TA and MG 
data are presented. 
During MVC trials, peak torque was calculated as the average 
torque at a maximum ±25-millisecond window, whereas agonist and 
antagonist mean root mean square electromyographic activity was 
determined using a 50-millisecond window at 50 milliseconds before 
maximum torque. Antagonist muscle co-contraction was quantified by 
dividing the antagonist muscle electromyographic activity by the 
agonist electromyographic activity of the same muscle acting as an 
antagonist (eg, MG co-contraction during plantarflexion was as 
follows: [MG electromyographic activity during dorsiflexion MVC]/[MG 
electromyographic activity during plantarflexion MVC]). During passive 
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trials, stretch reflexes were quantified as the peak plantarflexor torque 
during movements into dorsiflexion, with MG electromyographic 
activity quantified at that torque, and averaged at each speed (30–
120°/s). For the passive and active-assist trials, analysis focused on 
plantarflexor activity during dorsiflexion, with plantarflexion torque and 
mean MG electromyographic activity calculated during the mid-50% 
ramp of each active-assist cycle. Two passive and active-assist trials 
were averaged. 
Statistical analysis 
SPSS version 19f was used for statistical analysis with α=.05. No 
order effects were observed, and all data are compared between drug 
conditions. For MVC testing, the percent increases (post/pre) in torque 
and electromyographic activity were also compared between drug 
conditions using paired t tests. Torques and electromyographic 
responses during the passive and passive-active assist trials were 
compared using repeated-measures analysis of variance with testing 
condition (stretch velocity or trial number) and test condition (placebo 
or SSRI) as main factors, with post hoc Tukey-Kramer or paired 
comparisons. Pearson correlation coefficients were calculated to 
evaluate correlations between SSRI-induced changes in torque, clinical 
measures (Fugl-Myer, gait speed, 6MWD), and demographic 
characteristics (age, time since stroke). 
Results 
Eleven subjects were eligible and initiated the study, although 1 
felt “light-headed” 1 hour after SSRI ingestion and terminated 
participation before posttesting, with no adverse effects on follow-up. 
A total of 10 subjects (7 men) completed the entire experimental 
protocol. The mean age ± SD of the participants was 57±10 years, 
and the duration poststroke ± SD was 9.1±7.6 years. Patients 
presented with either ischemic (n=6; 4 cortical, 2 subcortical) or 
hemorrhagic (n=4) stroke (see table 1 for demographics). Four 
individuals received SSRIs during the first test. 
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Table 1. Demographics of 10 subjects who completed the study 
Subject 
No. 
Sex Age 
(y) 
Paresis 
(R/L) 
Pathology Chronicity (y) FM Score (1st 
Pretest) 
1 M 50 L Ischemic 5 20 
2 M 53 R Ischemic 4 23 
3 F 60 R Hemorrhagic 4 18 
4 M 71 R Hemorrhagic 19 23 
5 M 61 R Hemorrhagic 11 16 
6 F 35 R Ischemic 8 16 
7 M 50 R Hemorrhagic 3 15 
8 M 65 L Ischemic 6 18 
9 F 60 R Ischemic 5 19 
10 M 64 L Ischemic 26 18 
Abbreviations: F, female; FM, Fugl-Meyer; L, left; M, male; R, right. 
Effect of SSRIs on isometric MVCs 
A trend of increasing torques was observed with all paretic muscles 
tested, but with substantial variability and no significant differences 
after SSRI versus placebo conditions. For example, average 
plantarflexor torque increased by 25%±45% after SSRI administration 
(fig 2), but was not different after placebo administration (6%±15%; 
P=.10). Nonsignificant differences in MG activity were also observed 
(P=.10), with no differences in co-contraction (P=.45). Similar variable 
changes were observed with dorsiflexion (29%±79% vs 2%±16%, 
P=.28) and knee flexion torques (32%±56% vs –1%±33%, P=.07), 
with no differences in paretic extensors (P>.30). Correlation analyses 
revealed no significant relationships between baseline Fugl-Meyer 
scores and increases in peak volitional torques after SSRIs (all P>.05). 
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Fig 2. (A) Normalized (pre/post) MVC torques for lower limb muscle groups. Ankle 
dorsiflexion, ankle plantarflexion, knee flexion, and knee extension torque. (B) Pre- 
and postplacebo and pre- and post-SSRI MG co-contraction (root mean square MG 
electromyographic activity during flexion/root mean square MG electromyographic 
activity during extension) during dorsiflexion MVCs. Error bars represent SEM. 
Abbreviations: EMG, electromyographic; Mmax, M wave. 
Effect of SSRIs on plantarflexor stretch reflexes 
Reflex torques generated during passive stretch reflexes varied 
with stretch velocity, with greater increases post-SSRIs (fig 3A). 
Reflex torques increased from 30°/s to 120°/s trials in all test 
conditions (fig 3B). With significant analysis of variance (P<.05), post 
hoc testing indicated reflex torques at 90°/s trials were significantly 
increased post-SSRI vs placebo (115%±49% vs 48%±47%, P=.03). 
For 120°/s trials, differences in torque approached significance 
(P=.08). Increases in stretch reflex torques post-SSRI were not 
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correlated with Fugl-Meyer scores or other demographic or clinical 
data. 
 
Fig 3. Torque and MG electromyogram (EMG) during stretches of the plantar flexors. 
(A) Joint angle, torque, and MG EMG are shown for a single representative subject 
before and after SSRI. The torque in this figure is before subtraction of the passive 
trials. (B) Grouped mean peak torque generated during the dorsiflexion perturbation 
ramps (plantarflexor stretch) at different speeds. Error bars show the SEM. *P<.05. 
Abbreviation: PF, plantarflexion. 
Effect of SSRIs on passive and active-assist responses 
The effects of SSRIs on stretch reflexes during superimposed 
voluntary drive was tested with 6 consecutive stretch cycles, with 
passive trials for the first, fifth, and sixth cycles, and volitional activity 
during the second to fourth cycles (active assist). Despite attempts at 
dorsiflexion during the second to fourth cycles, reflex torques were 
observed at the end of the movement (fig 4A). As subjects relaxed 
(fifth to sixth cycles), elevated electromyographic activity and torque 
measures during rotations reflected the residual effect of volitional 
drive on stretch reflex excitability, and were compared to the first 
passive cycle. These effects were enhanced with SSRIs, with 
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significant repeated-measures intervention for cycle and testing 
condition. Post hoc comparisons suggested no differences during the 
first passive cycle (P=.87) ( fig 4B). During the active-assist cycles 
(cycles 2–4), plantarflexor reflexes were substantially greater post-
SSRI vs placebo (P=.08, .02, and .02, respectively). Specifically, 
increases at the third to fourth cycles were approximately 2.5-fold 
greater with SSRIs as compared with approximately 1.3-fold greater 
with placebo. Elevated reflex responses appeared to carry-over into 
subsequent passive cycles, with torque increases approaching 
significance at the fifth cycle (P=.07) but no differences at the sixth 
cycle. 
 
Fig 4. (A) Passive and active-assist trials of a representative subject pre- and post-
SSRI. Gray vertical bars represent the middle 50% of the dorsiflexion ramp. The 
increment in torque and the MG root mean square electromyographic activity that 
occurred within this interval were calculated. (B) Grouped changes in torques during 
these intervals across the 6 cycles. Data represent the mean values across 10 subjects 
with error bars representing SEM. Abbreviation: EMG, electromyogram. 
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Clinical measures 
There were no differences in changes in 6MWD, fastest gait 
speed, and lower limb Fugl-Meyer scores across test sessions, with 
mean changes of less than 10% of baseline after either SSRIs or 
placebo (fig 5). 
 
Fig 5. Assessment of motor performance and gait pre- and postplacebo or pre- and 
post-SSRI. (A) Distance covered during 6-minute walk. (B) Gait speed during fast 
walking. (C) Lower limb Fugl-Meyer score. Bars represent the average values across 
all subjects, and error bars show SEM. 
Discussion 
In the present study, SSRIs demonstrated a significant increase 
in plantarflexor stretch reflexes in patients poststroke at faster 
perturbation speeds, which was enhanced with superimposed 
voluntary drive. No significant increase in any measure of strength or 
functional outcomes was observed after SSRIs. Increased spasticity 
has not been reported previously in patients poststroke after SSRI 
administration, and only studies in patients with SCI have indicated 
increased SSRI-induced spasticity. 
Effects of SSRIs on stretch reflex excitability 
Increased stretch reflexes with enhanced 5-HT transmission are 
consistent with results from animal models with increased descending 
5-HT after decerebration, raphe electrical stimulation,45 or spinalization 
with 5-HT precursors.46 We believe increased 5-HT was the likely 
primary determinant of increased velocity-dependent stretch reflexes 
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observed here, consistent with clinical measures of increased spasticity 
in subjects with SCI.30,31 Greater increases in stretch reflexes were 
also observed during the active-assist cycles, with increased activity at 
speeds (60°/s) at which little effect was seen in the “passive-only” 
trials. We believe this increased spasticity may be related to elevated 
descending 5-HT pathways during repetitive rhythmic MVCs,22 which 
provided a greater substrate for action of the SSRIs. The resulting 5-
HT modulation of spinal circuits24 could result in depolarization of 
motoneurons and selected interneurons and amplification of persistent 
inward currents,25, 47,48 thereby increasing motor output with specific 
afferent inputs. 
Minimal changes in single MVCs or clinical assessments 
The absence of significant gains in MVCs with little co-activation 
or lack of improvements in functional measures was surprising given 
the published data in upper extremity studies of patients 
poststroke.17,26 One explanation may be assessment of lower extremity 
function in the present study, where direct cortical projections to lower 
versus upper extremity motor pools in humans are more limited, such 
that increased motor cortical excitability may not sufficiently increase 
descending commands to increase peak force output. However, 
patients with incomplete SCI demonstrate increases in strength,30 
suggesting that differences in tested populations may also contribute. 
Conversely, another explanation to account for nonsignificant 
increases in MVCs is the use of discrete single contractions of a limited 
duration, which may cause a more limited increase in activity of 
brainstem 5-HT neurons.49,50 Single MVCs may not have sufficiently 
increased 5-HT release, thus providing a more limited response with 
SSRIs. Indeed, greater changes in upper limb motor function in 
patients poststroke are observed with brief bouts of task practice, and 
that may influence the present results. 
A related finding was the minimal improvements in walking 
function. While locomotion is associated with increased 5-HT activity, 
the nonsignificant increases in strength with significant gains in 
spasticity could have limited functional performance. More detailed 
biomechanical and electromyographic analyses during walking after 
SSRIs are necessary to identify specific locomotor changes,51 
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particularly to indicate whether altered muscle activity contributed to 
changes in walking function. Regardless, the present data are 
consistent with selected studies in animal models52 and humans of 
neurologic injury (SCI)51 indicating no immediate improvements in 
locomotion function with single-dose enhancement of 5-HT 
transmission. These findings are of clinical interest because previous 
data suggest improvements in motor function after prolonged SSRI 
use, although greater changes were observed in upper versus lower 
limbs.19 Further study is certainly necessary to address the potential 
effects of SSRIs on lower limb function poststroke in single or repeated 
doses and combined with rehabilitation. 
Study limitations 
The main limitation of the present work is the small sample size. 
Sample estimates were, however, based on published power analyses 
on the effects of single-dose SSRI on patients with neurologic injury,30 
although the present sample was sufficient to observe differences in 
spastic responses. These relative changes suggest “positive” UMN 
signs may be influenced more in the lower extremity poststroke with 
SSRIs than weakness. Further studies are necessary to evaluate what 
clinical or demographic factors determine responsiveness to SSRIs. 
An additional limitation is the effects of multiple testing 
procedures on patient performance and potential fatigue during 
testing. The use of a randomized blinded trial design with identical 
order of procedures was necessary to ensure this limitation did not 
selectively alter outcomes, and this limitation may be difficult to 
overcome in these and similar studies. 
Finally, the present study was limited to the use of only single-
dose effects of escitalopram as opposed to other SSRIs that have been 
tested. The single-dose effects were studied to minimize habituation to 
the tested agents,27,29 although greater effects on motor function, 
including both volitional and reflex behaviors, may be enhanced with 
prolonged doses.34 Further, escitalopram was chosen because of 
potential increased clinical use given its greater efficacy for depressive 
disorders.53 Whether similar effects would be observed with other 5-HT 
agents is not clear, although previous data suggest a similarity in 
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changes in motor excitability or performance with various 
SSRIs.17 and 20 
Conclusions 
In summary, single doses of SSRIs did not enhance 
performance of lower limb voluntary tasks in chronic stroke subjects 
but rather increased spastic motor activity. This effect was enhanced 
during repetitive volitional tasks. Increased spastic behaviors with little 
improvement in function may be considered a potential adverse effect 
of SSRIs when prescribing these agents to chronic poststroke subjects 
for depressive symptoms. The lack of improvements in lower limb 
function with SSRIs may also be important given the results of recent 
positive trials on upper limb function, and suggests that more work 
should be done to investigate their global effects. 
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